Results 191 to 200 of about 90,167 (303)

Emerging biological therapies for psoriatic arthritis: A systematic review. [PDF]

Medicine (Baltimore)
Firdous S, Amjad H, Choudhary MU, Afzal MW, Tayyab RH, Parveen A.   +5 more
europepmc   +1 more source

Severe Delayed Hypersensitivity Reaction at Guselkumab Injection Site

Contact Dermatitis, EarlyView.
Salomé Allichon, Julie Litovsky, Michèle Sanchez, Céline Girard, Guillaume Granier, Luc Durand, Maxime Henrion, Christelle Philibert, Cosette Le Souder, Nadia Raison‐Peyron   +9 more
wiley   +1 more source

Characteristics and Contributing Factors for Difficult to Treat Psoriatic Arthritis- a Comparative Analysis. [PDF]

J Psoriasis Psoriatic Arthritis
Ping Seung O, Jia LP.
europepmc   +1 more source

The epidemiology of psoriatic arthritis in Israel – a population-based study [PDF]

, 2018
Lihi Eder, Arnon D. Cohen, Ilan Feldhamer, Sari Greenberg‐Dotan, Erez Batat, Devy Zisman   +5 more
openalex   +1 more source

Successful treatment of palmoplantar pustulosis with topical ruxolitinib

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Neda Cramer, Phoebe Wellmann, Michael P. Schön, Rotraut Mössner   +3 more
wiley   +1 more source

Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68‐week randomized Phase 3 trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This open‐label study is a continuation of the 16‐week double‐blind, Phase 3 trial assessing the efficacy and safety of brodalumab 210 mg subcutaneously, till a 68‐week extension period. Continued improvement was seen in the PPPASI 50/75/90 responses, PPPSI scores, PGA 0/1 responses and DLQI. Abstract Background The efficacy and safety of brodalumab in
Masamoto Murakami, Yukari Okubo, Satomi Kobayashi, Natsuko Kikuta, Yoshiumi Ouchi, Kenta Shishido, Tadashi Terui   +6 more
wiley   +1 more source

An Unusual Case of Psoriatic Arthritis With Peliosis Hepatis. [PDF]

Cureus
Zerouali B, Nassar K, Zaher S, Bennani Guebessi N, Janani S.   +4 more
europepmc   +1 more source

CXCL4 is a novel inducer of human Th17 cells and correlates with IL‐17 and IL‐22 in psoriatic arthritis [PDF]

, 2017
Alsya J. Affandi, Sandra C. Silva‐Cardoso, Samuel García, Emmerik F A Leijten, Tessa S. van Kempen, Wioleta Marut, Joël A. G. van Roon, Timothy R. D. J. Radstake   +7 more
openalex   +1 more source

Feasibility and usability of three consecutive nights with self‐applied, home polysomnography

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary In‐laboratory polysomnography, the gold‐standard for diagnosing sleep disorders, is resource‐demanding and not conducive to multiple night evaluations. Ambulatory polysomnography, especially when self‐applied, could be a viable alternative. This study aimed to assess the feasibility and reliability of self‐applied polysomnography over three ...
Dimitri Ferretti, Anna S. Islind, Kristín A. Ólafsdóttir, Sigridur Sigurdardottir, Kamilla R. Jóhannsdóttir, Jan Hedner, Ludger Grote, Erna Sif Arnardottir   +7 more
wiley   +1 more source

Impact of Delay of Treatment With Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: The CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. [PDF]

ACR Open Rheumatol
Mease PJ, Nowak M, Choi J, Lehman T, Sreih A, Ho K, Middaugh N, Ogdie A.   +7 more
europepmc   +1 more source